[HTML][HTML] Systemic bevacizumab for recurrent respiratory papillomatosis: a single center experience of two cases

A Bedoya, K Glisinski, J Clarke, RN Lind… - The American Journal …, 2017 - ncbi.nlm.nih.gov
Objective: Unusual clinical course Background: Recurrent respiratory papillomatosis (RRP),
caused by human papillomavirus (HPV), is the most common benign neoplasm of the larynx …

Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian …

F Collette, G Lawson, S Hassid, G Delahaut… - Head & …, 2023 - Wiley Online Library
Background Recurrent respiratory papillomatosis (RRP) is a currently incurable benign
neoplasm caused by human papilloma virus (HPV) infection. It usually reduces voice …

Long‐term follow‐up on systemic bevacizumab treatment in recurrent respiratory papillomatosis

G Evers, C Schliemann, A Beule, LH Schmidt… - The …, 2021 - Wiley Online Library
Objectives/Hypothesis Recurrent respiratory papillomatosis (RRP) is a primarily benign
disease affecting the entire respiratory tract. Treatment is challenging and usually involves …

Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey

SR Best, M Mohr, KB Zur - The Laryngoscope, 2017 - Wiley Online Library
Objectives/Hypothesis Aggressive laryngeal, tracheal, and pulmonary papilloma is an
extremely challenging clinical problem without proven treatment options. A recent German …

Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review

L Pogoda, F Ziylan, DPJ Smeeing, FG Dikkers… - European Archives of …, 2022 - Springer
Purpose To this day, there is no cure for recurrent respiratory papillomatosis (RRP). Multiple
surgical procedures are performed to achieve symptom relief and prevention of airway …

Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis

M Mohr, C Schliemann, C Biermann… - Oncology …, 2014 - spandidos-publications.com
Recurrent respiratory papillomatosis (RRP) is a primary benign disease, which is
characterized by papillomatous growth in the respiratory tract. Malignant transformation …

Long‐term follow‐up of parenteral bevacizumab in patients with recurrent respiratory papillomatosis

SA Ballestas, J Hidalgo Lopez, AM Klein… - The …, 2023 - Wiley Online Library
Objective The clinical course of recurrent respiratory papillomatosis (RRP) varies from
spontaneous remission to severe airway obstruction with wide variability in recurrence …

[HTML][HTML] Systemic use of bevacizumab for recurrent respiratory papillomatosis: who, what, where, when, and why?

CS Derkay, EE Wikner, S Pransky, SR Best… - The …, 2023 - ncbi.nlm.nih.gov
BACKGROUND Recurrent respiratory papillomatosis (RRP) is a potentially lethal disease
caused by the human papillomavirus (HPV) and characterized by recurrent papillomas in …

Systemic bevacizumab treatment for recurrent respiratory papillomatosis: long‐term follow‐up

R Ruiz, N Balamuth, LR Javia, KB Zur - The Laryngoscope, 2022 - Wiley Online Library
Objectives/Hypothesis Systemic bevacizumab is a new adjuvant therapy for recurrent
respiratory papillomatosis (RRP) that has shown promising preliminary results in children …

Parenteral bevacizumab for the treatment of severe respiratory papillomatosis in an adult population

A Tkaczuk, S Trivedi, MD Mody, CE Steuer… - The …, 2021 - Wiley Online Library
Objectives/Hypothesis Recurrent respiratory papillomatosis (RRP) is a rare, potentially life‐
threatening, disease that impacts the voice, breathing, and quality of life of patients …